Immuno-Oncology | Specialty

Dr. Spigel on CheckMate-331 Trial for SCLC

June 29th 2016

David Spigel, MD, chief scientific officer, director, Lung Cancer Research Program, principal investigator, Sarah Cannon Research Institute, discusses the ongoing CheckMate-331 trial, which is investigating nivolumab (Opdivo) versus chemotherapy in relapsed patients with small cell lung cancer (SCLC) after first-line platinum-based chemotherapy.

KEYNOTE-012 Investigator Explains Promise of Pembrolizumab in HNSCC

June 29th 2016

Ranee Mehra, MD, discusses what the KEYNOTE-012 findings could mean for patients, the growing role for the immunotherapy agent in head and neck cancer, and what else is on the horizon for the treatment landscape.

CHMP Recommends Approval of Pembrolizumab for Lung Cancer

June 28th 2016

The EMA's Committee for Medicinal Products for Human Use has granted a positive opinion for use of pembrolizumab (Keytruda) as a treatment for patients with locally advanced or metastatic PD-L1-positive non–small cell lung cancer.

FDA Grants Nivolumab Breakthrough Designation for Advanced Bladder Cancer

June 28th 2016

The FDA has granted nivolumab (Opdivo) a breakthrough therapy designation for the treatment of patients with unresectable locally advanced or metastatic urothelial carcinoma after the failure of a platinum-containing regimen.

Dr. Andtbacka on Optimal Use of T-VEC in Melanoma

June 27th 2016

Robert Andtbacka, MD, associate professor in the Division of Surgical Oncology, Department of Surgery at the University of Utah School of Medicine, discusses the optimal use of talimogene laherparepvec (T-VEC) in patients with melanoma.

First-in-Human CRISPR Immunotherapy Would Target PD-1

June 24th 2016

At a time when PD-1 inhibitors are dominating the immunotherapy field, a team of researchers is seeking to use groundbreaking CRISPR gene editing technology for the first time in human beings to create an engineered T-cell agent that would knock out the gene that controls the immune checkpoint’s activity.

Expert Sheds Light on Promising Immunotherapy Combo Data in mCRC

June 23rd 2016

Michael J. Overman, MD, discusses the findings of the phase II CheckMate-142 study, which examined nivolumab (Opdivo) and ipilimumab (Yervoy) in patients with high microsatellite instability colorectal cancer.

Emerging Immunotherapy Target in Spotlight at Wistar

June 22nd 2016

Amid growing evidence of their importance in the immune system, myeloid-derived suppressor cells are gaining traction as a target for anticancer therapies.

Dr. Mehra on KEYNOTE-012 Results of Pembrolizumab in Head and Neck Cancer

June 22nd 2016

Ranee Mehra, MD, chief, Head and Neck Hematology/Oncology, associate professor, Department of Hematology/Oncology, Fox Chase Cancer Center, discusses the results of the KEYNOTE-012 study, which examined the efficacy of pembrolizumab (Keytruda) in patients with recurrent/metastatic head and neck squamous cell carcinoma.

Dr. Mark Kris on Immunotherapy and Frontline Options for Patients With NSCLC

June 18th 2016

Mark G. Kris, MD, medical oncologist, William and Joy Ruane Chair in Thoracic Oncology, Memorial Sloan Kettering Cancer Center, explains what community oncologists need to know regarding immunotherapy and frontline treatment options for patients with non–small cell lung cancer (NSCLC).

Frontline Pembrolizumab Improves Survival in NSCLC Patients With High PD-L1 Expression

June 17th 2016

Frontline pembrolizumab (Keytruda) improved overall survival versus chemotherapy in non–small cell lung cancer patients with high levels of PD-L1 expression.

Dr. Overman on Nivolumab and Ipilimumab in Patients With MSI-H CRC

June 15th 2016

Michael J. Overman, MD, associate professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses a study examining nivolumab (Opdivo) monotherapy, ipilimumab (Yervoy) monotherapy, and the combination of nivolumab and ipilimumab in patients with high microsatellite instability metastatic colorectal cancer.

Atezolizumab and Cobimetinib Regimen Shows Activity in CRC

June 15th 2016

In patients with advanced colorectal cancer, the combination regimen of cobimetinib (Cotellic) and atezolizumab (Tecentriq) was found to demonstrate clinical activity as well as have a good safety profile.

Expert Discusses Long-Term Survival, Next Steps With Nivolumab in RCC

June 15th 2016

David F. McDermott, MD, provides further insight on the long-term efficacy and safety of nivolumab and its role in renal cell carcinoma, as well as potential combination regimens and challenges with sequencing nivolumab.

Dr. Rafii on Durvalumab in Patients With Urothelial Bladder Cancer

June 14th 2016

Saeed Rafii, MD, PhD, medical director, Sarah Cannon Research Institute, United Kingdom, discusses a phase I/II dose-escalation study examining the efficacy and safety of the PD-1 antibody durvalumab in patients with metastatic urothelial bladder cancer.

Dr. Jeffrey Weber on CheckMate-064 Trial for Advanced Melanoma

June 13th 2016

Jeffrey S. Weber, MD, PhD, deputy director and co-director of the Melanoma Program, Laura and Isaac Perlmutter Cancer Center at NYU Langone Medical Center, discusses the design and results of the CheckMate-064 trial, which examined outcomes in patients who received nivolumab (Opdivo) given sequentially with ipilimumab (Yervoy) in patients with advanced melanoma.

Dr. Sandra Demaria on Radiation and Immunotherapy Combination Regimens

June 10th 2016

Sandra Demaria, MD, assistant professor of Radiation Oncology, (Interim), Radiation Oncology, Weill Cornell Medical College and New-York Presbyterian, discusses the synergy with radiation therapy and immunotherapy as a potential combination regimen for patients with cancer.

T-VEC/Pembrolizumab Combo Shows Early Promise in Advanced Melanoma

June 10th 2016

The combination of the oncolytic virus talimogene laherparepvec (T-VEC) and pembrolizumab (Keytruda) demonstrated evidence of clinical benefit, as well as an acceptable safety profile, in patients with advanced melanoma.

Expert Discusses 2-Year Nivolumab Data and Other Immunotherapy Developments in NSCLC

June 10th 2016

Hossein Borghaei, DO, discusses the significance of the 2-year follow-up results of the CheckMate-057 and -017 studies, the evolving role of PD-L1 as a biomarker and others that are in development, and emerging immunotherapy agents in the field of non-small cell lung cancer.

Dr. Melissa Johnson on Atezolizumab in Patients With NSCLC

June 10th 2016

Melissa Johnson, MD, associate director, Lung Cancer Research, Sarah Cannon Research Institute, discusses the phase II BIRCH study, which is examining atezolizumab (Tecentriq) in patients with PD-L1–positive locally advanced or metastatic non–small cell lung cancer (NSCLC).